Our third quarter results demonstrate the strength of our broad portfolio and our team’s disciplined execution. Adoption of our innovative technologies is driving strong growth and expanding profitability, while the rapid progress of our BoxX-NoAF clinical trial reinforces our confidence in the opportunities ahead. We are well positioned to extend our leadership in cardiac surgery and post-operative pain management, creating lasting value for patients and our shareholders.
bit.ly/482IX90
bit.ly/482IX90